NCT01663012View on ClinicalTrials.gov

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Anaplastic AstrocytomasAnaplastic OligodendrogliomasGlioblastomas (GBM)
Interventions
DRUG

Etirinotecan pegol

Trial Locations (1)

94305

Stanford University School of Medicine, Palo Alto

Sponsors

Collaborators (1)

Nektar Therapeutics
All Listed Sponsors
collaborator

Nektar Therapeutics

INDUSTRY

lead

Lawrence Recht

OTHER